December 1, 2022
The Generics and Biosimilars Initiative (GaBI) has published a report on the first of two webinars the organization recently co-hosted with ASBM. The report summarizes the presentations from the June 29th webinar which examined “Key Factors for Successful Biosimilar Uptake in Europe, Canada and the US”. View the webinar below: The report also addresses audience questions that were unable to be […]
July 5, 2022
On July 20th, 2022 ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a 2-hour webinar entitled “Non-Medical Switching of Biologicals and Biosimilars: Canada, Europe, and the US” The event offered an overview of non-medical switching practices in different regions and focused on the importance of safeguarding the patient-physician relationship. Watch the webinar here. Academic […]
June 1, 2022
On May 31st, the Ohio State University College of Pharmacy released a series of promotional videos for its 7-hour continuing education (CE) program on biosimilars. The videos consist of an overview of the educational program featuring all the presenters, as well as a biographical sketch of each presenter. The program was developed in partnership with ASBM […]
June 1, 2022
On June 29th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled “Key Factors for Successful Uptake of Biosimilars: Europe and the US: measures taken for improving biosimilar uptake and the potential role of healthcare providers and patients”. The event featured a keynote presentation by former U.S. Deputy Secretary of Health and Human Services […]
June 1, 2022
On June 29th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled “Key Factors for Successful Uptake of Biosimilars: Europe and the US: measures taken for improving biosimilar uptake and the potential role of healthcare providers and patients”. The event featured a keynote presentation by former U.S. Deputy Secretary of Health and Human Services […]
February 23, 2012
Presented by Dr. Richard Dolinar, MD What is pharmacovigilance Track & Trace systems for biologic medicines Coding, Naming, Labeling Down the Road: Interchangeability and Drug Substitution
December 1, 2011
Presented by Dr. Richard Dolinar, MD What are biosimilars Why are biosimilars not generics Manufacturing The FDA’s “biosimilar pathway” Policy Considerations
December 1, 2011
Presented by Dr. Richard Dolinar, MD What are biosimilars Why are biosimilars not generics Manufacturing The FDA’s “biosimilar pathway” Policy Considerations
November 17, 2011
Presented by Alliance Chairman, Dr. Richard Dolinar, MD Role of biotechnology in medical advancements What are biologics Examples of biologic medicines Manufacturing process Chemical drugs vs. biologic medicines Implications of size, variability, complexity What’s next for biotechnology
